看见一个 Expert Review of Anticancer Therapy。你们前面用依维莫斯,血、肝肾功能还好。下一步是否考虑索拉非尼+依维莫斯。供你参考。/ E: l6 ~ v: M, R
0 ~" s& R7 l# y/ u C+ u1 E9 W# @" m# Q& {0 j
Currently available feasibility data for possible combination strategies. - X0 F2 i( Q n, W" K$ W
————————————————————————————————, _. @3 i3 Q- |
Combination Feasibility according to preliminary data
z% V9 m( W9 q: E8 Z, Z( i r& j——————————————————————————————————* \' x# M( F1 C+ y1 ?3 m7 X1 e
Bevacizumab + sorafenib Yes, reduced dose H/ [5 e& a% d q' S N
Bevacizumab + sunitinib† No
7 j: U& n& y& M5 D7 ]Bevacizumab + temsirolimus Yes
! \9 T2 v4 R' P, n# t6 L9 zBevacizumab + everolimus Yes 2 e4 W) U% j, \
Sorafenib + sunitinib ? 0 F% k: F+ |5 K! M& f$ N$ N7 I, \$ P
Sorafenib + temsirolimus Yes, reduced dose 8 x k, B) j& W k2 U
Sorafenib + everolimus Yes, reduced dose ' V& a4 `3 Y( ^) c5 J7 K
Sunitinib + temsirolimus† No + Y! }. r: }# ~, o: i
Sunitinib + everolimus ?
( U( k; t m" x0 ~4 r7 L2 lTemsirolimus + everolimus ?
, _5 X6 W: E B; D————————————————————. j* { b7 d4 Q0 D4 A3 L- f
†Led to US FDA warning.
! V6 @+ @) V# k/ B1 J7 i: P/ i( n?: As yet unattempted combination.
! Q/ M$ N4 D5 Y |